The FDA has authorized Novavax's updated COVID-19 vaccine for emergency use in individuals aged 12 and older, targeting the JN.1 strain of the virus. This decision allows Novavax to compete with recently approved mRNA vaccines from Pfizer and Moderna, which target the KP.2 variant. Novavax's protein-based vaccine offers an alternative for those hesitant to receive mRNA shots, as it uses a traditional method for immunization. Local pharmacies are already distributing the updated vaccines amid rising COVID-19 hospitalization rates in regions like South-central Minnesota, where hospitalizations have increased significantly compared to last year. Public health officials are concerned about waning immunity as the cold season approaches, emphasizing the importance of vaccination. Despite the recent approval, it remains uncertain how many individuals will opt for the new vaccines this fall and winter.